ADMA Biologics Inc (NASDAQ:ADMA) Position Reduced by Federated Hermes Inc.

Key Points

• Federated Hermes Inc. has decreased its stock position in ADMA Biologics Inc. by 7.9%, now holding approximately 1.2 million shares valued at nearly $23.9 million.
• Several hedge funds, including Farther Finance Advisors LLC and CIBC Private Wealth Group LLC, have also made significant changes to their positions in ADMA Biologics, indicating a robust interest from institutional investors.
• ADMA Biologics reported earnings that missed estimates, with a 40.2% increase in revenue year-over-year, highlighting a divergence between strong revenue growth and earnings performance.

Federated Hermes Inc. trimmed its stake in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 7.9% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 1,204,127 shares of the biotechnology company's stock after selling 102,809 shares during the quarter. Federated Hermes Inc. owned approximately 0.51% of ADMA Biologics worth $23,890,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of ADMA. Vanguard Group Inc. grew its holdings in ADMA Biologics by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 18,198,796 shares of the biotechnology company's stock worth $312,109,000 after buying an additional 80,302 shares in the last quarter. JPMorgan Chase & Co. boosted its position in ADMA Biologics by 272.5% during the 4th quarter. JPMorgan Chase & Co. now owns 767,265 shares of the biotechnology company's stock worth $13,159,000 after acquiring an additional 561,310 shares during the period. Norges Bank bought a new position in shares of ADMA Biologics in the fourth quarter worth $2,047,000. New Age Alpha Advisors LLC acquired a new position in shares of ADMA Biologics during the fourth quarter valued at $221,000. Finally, Pictet Asset Management Holding SA increased its holdings in shares of ADMA Biologics by 10.5% during the fourth quarter. Pictet Asset Management Holding SA now owns 30,885 shares of the biotechnology company's stock valued at $530,000 after purchasing an additional 2,928 shares during the period. Institutional investors and hedge funds own 75.68% of the company's stock.

ADMA Biologics Price Performance

Shares of ADMA stock traded up $0.63 during mid-day trading on Friday, hitting $19.33. 2,469,666 shares of the stock traded hands, compared to its average volume of 2,296,092. ADMA Biologics Inc has a twelve month low of $10.21 and a twelve month high of $25.67. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.36 and a current ratio of 6.58. The company's 50-day simple moving average is $18.83 and its 200-day simple moving average is $18.73. The firm has a market cap of $4.61 billion, a price-to-earnings ratio of 22.74 and a beta of 0.38.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. The firm had revenue of $114.80 million for the quarter, compared to analyst estimates of $116.40 million. During the same period in the previous year, the firm earned $0.08 earnings per share. ADMA Biologics's revenue was up 40.2% on a year-over-year basis. As a group, equities research analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ADMA. Raymond James Financial upped their price objective on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a report on Thursday, May 8th. Wall Street Zen lowered shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th.

Insider Transactions at ADMA Biologics

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 20,000 shares of the company's stock in a transaction on Monday, June 9th. The stock was sold at an average price of $20.96, for a total value of $419,200.00. Following the transaction, the director owned 94,830 shares of the company's stock, valued at approximately $1,987,636.80. This represents a 17.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jerrold B. Grossman sold 10,000 shares of the stock in a transaction on Monday, June 9th. The shares were sold at an average price of $21.31, for a total value of $213,100.00. Following the sale, the director owned 478,194 shares of the company's stock, valued at $10,190,314.14. This trade represents a 2.05% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 464,621 shares of company stock valued at $9,644,269 in the last quarter. Insiders own 3.50% of the company's stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.